

South Dakota Department of Social Services, Division of Medicaid Services Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, December 13, 2019

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Bill Ladwig, RPh	X
Dana Darger, RPh, Chair	X	Kelley Oehlke, PharmD	
James Engelbrecht, MD	X	Lenny Petrik, PharmD	X
Deidre Van Gilder, PharmD	X	Mike Jockheck, DSS Staff	X
Mikal Holland, MD		Sarah Akers, DSS Staff	X
Richard Holm, MD		Bill Snyder, DSS Staff	X

Administrative Business

Darger called the meeting to order at 1:02 PM. The minutes of the June meeting were presented. Ladwig made a motion to approve. Van Gilder seconded the motion. Motion was approved unanimously.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from July 1, 2019 to September 30, 2019. A total of 1,884 PAs were reviewed of which 296 requests (15.71%) were received via telephone and 1,063 requests (56.42%) were received via fax, and 525 (27.87%) were reviewed via electronically.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from July 1, 2019 to September 30, 2019. The top five therapeutic classes based on paid amount were atypical antipsychotics, disease-modifying anti-rheumatic agents, anticonvulsants, amphetamines, and respiratory/CNS stimulants. The top 15 therapeutic classes make up 24.77% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 7.43% of total claims. Darger and Ladwig discussed USP Chapter 800 Standards for Safe Handling of Hazardous Drugs. They requested utilization of compound claims to review at the next meeting.

Old Business

The committee reviewed the calcitonin gene related peptide (CGRP) utilization comparing 2Q19 vs 3Q19. Utilization continues to increase each quarter, including utilization shift from Aimovig to Emgality. Petrik commented seeing similar utilization shifts on the commercial plan side. The committee also reviewed utilization for Orilissa for 3Q19. Committee requested to review utilization for both classes again at the next meeting.

The committee reviewed 3Q19 opioid outcomes compared to previous quarters from the opioid initiatives. Utilization and MME levels indicate decreased trend.

New Business

PA Criteria Review

The committee reviewed all PA criteria currently in effect. Jockheck reminded the committee to also consider removing PAs that are not necessary due to availability of generics, outdated, or now considered out of scope. The following decisions were made, including requesting follow up information for a more in-depth review at the next meeting:

- Lyrica – Committee reviewed utilization for Lyrica and pregabalin for PA removal consideration. Darger requested to review gabapentin utilization at the next meeting before making a decision. It was suggested to also include duloxetine utilization and how other Medicaid states were handling Lyrica, especially surrounding areas.
- Hepatitis C – Snyder provided an update regarding the committee’s recommendation from the June meeting. DSS continues to evaluate the recommendation.
- Lidoderm – Darger requested utilization for Lidoderm.
- Ketoconazole Topical – Committee inquired if there were PAs for Extina or Xolegel.
- Head Lice – Committee reviewed utilization and discussed the merits of this PA. Darger commented the PA was developed because of heavy utilization of lindane since providers did not know OTC permethrin was covered. In addition, the potential for Soolantra cream (indications for rosacea) used for head lice treatment was discussed.
- Topical Acne – Committee reviewed utilization for topical acne and rosacea treatment. Baack made a motion to create a rosacea PA. Van Gilder seconded the motion. Motion was approved unanimously.
- Growth Hormones – Baack made a motion to modify PA criteria from “for small gestational age (SGA)” to “for small gestational age plus post-natal growth failure at one year”. Ladwig seconded the motion. Motion was approved unanimously.
- Anticoagulants – Van Gilder questioned the need for a PA. Darger commented drugs are used appropriately and suggested monitoring utilization when PA removed. Van Gilder made a motion to remove PA on Eliquis, Pradaxa, Savaysa, and Xarelto. Baack seconded the motion. Motion was approved unanimously.
- Triptans – Ladwig requested to review utilization prior to consideration for PA removal.
- Nasal Steroids – Ladwig requested to review utilization prior to consideration for PA removal.
- Methadone – After discussing previous reasons for the PA on methadone and since it is part of the long-acting-opioid (LAO) PA and MED Limit PA, Ladwig made a motion to remove PA. Baack seconded the motion. Motion was approved unanimously.
- Ophthalmic Antihistamines – Committee reviewed utilization for ophthalmic antihistamines. Ladwig made a motion to remove PA on olopatadine ophthalmic drops. Van Gilder seconded the motion. Motion was approved unanimously.

Engelbrecht made a motion to approve all the PA criteria as amended today. Baack seconded the motion. Motion was approved unanimously.

Ladwig requested reviewing GLP-1 orals at the next meeting.

Review of Sunosi

Sunosi clinical information was presented for review. Committee recommended adding Sunosi to Xyrem PA. Ladwig made a motion to add PA to Sunosi. Engelbrecht seconded the motion. Motion was approved unanimously.

Review of Apadaz

Apadaz clinical information was presented for review. Apadaz is included in the MED Limit PA. Committee recommended adding Apadaz to LAO PA. Engelbrecht made a motion to add PA to Apadaz. Ladwig seconded the motion. Motion was approved unanimously.

Engelbrecht Retirement

Darger read Governor Noem's proclamation designating December 13 as James Engelbrecht Day who devoted his life service to medical practice for the last 45 years. Engelbrecht is retiring after the December 13th meeting. Engelbrecht has been on the committee for the last 16 years. He stated this was the best committee he has served on where experts from pharmacy and medical come together to serve the community of South Dakota.

Adjournment

The next meeting is scheduled for March 13, 2019. Tentative meeting dates for next year are June 5, 2020. Engelbrecht announced as a point of personal preference made a motion to adjourn the meeting and the committee seconded the motion. The motion passed unanimously, and the meeting adjourned at 2:32 PM.